David van Veenhuyzen

Statistics

Publications

Citations

505

H-Index

Active since

2010

Affiliations

Shionogi (United States)(Current)

Shionogi (Japan)

Bayer (United States)

David van Veenhuyzen is an author at Shionogi (United States) specializing in antimicrobial pharmacotherapy, pharmacotherapy, and antimicrobial pharmacology.

Publications per year

2010–2018

Publications

Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial

Simon Portsmouth, David van Veenhuyzen, Roger Echols et al. · The Lancet Infectious Diseases · 2018 · 404 citations

Life Sciences, Infectious Diseases, Microbiology +10

Update on the Cardiac Safety of Moxifloxacin

Wilhelm Haverkamp, Frank Kruesmann, Anna Fritsch et al. · Current Drug Safety · 2012 · 44 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Moxifloxacin five‐day therapy versus placebo in acute bacterial rhinosinusitis

James A. Hadley, Ralph Mösges, Martin Desrosiers et al. · The Laryngoscope · 2010 · 31 citations

Medicine, Otolaryngology, Pharmacotherapy +11

Clinical Response of Cefiderocol Compared with Imipenem/Cilastatin in the Treatment of Adults with Complicated Urinary Tract Infections with or without Pyelonephritis or Acute Uncomplicated Pyelonephritis: Results from a Multicenter, Double-blind, Randomized Study (APEKS-cUTI)

Simon Portsmouth, David van Veenhuyzen, Roger Echols et al. · Open Forum Infectious Diseases · 2017 · 26 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +15

1–4 of 4